Stay updated on Ledipasvir/Sofosbuvir 12-Week Combo in Genotype 2 HCV Clinical Trial

Sign up to get notified when there's something new on the Ledipasvir/Sofosbuvir 12-Week Combo in Genotype 2 HCV Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ledipasvir/Sofosbuvir 12-Week Combo in Genotype 2 HCV Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the antiviral efficacy evaluation of therapy with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) for participants with chronic genotype 2 hepatitis C virus (HCV) infection.
    Difference
    0.2%
    Check dated 2024-06-06T14:26:50.000Z thumbnail image
  6. Check
    20 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying that researchers are looking for chronic genotype 2 HCV-infected males and non-pregnant/non-lactating females aged 20 years or older, among other criteria. Previously, this section had no information provided.
    Difference
    13%
    Check dated 2024-05-22T21:09:10.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Difference
    2%
    Check dated 2024-04-30T22:48:33.000Z thumbnail image

Stay in the know with updates to Ledipasvir/Sofosbuvir 12-Week Combo in Genotype 2 HCV Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ledipasvir/Sofosbuvir 12-Week Combo in Genotype 2 HCV Clinical Trial page.